Canaccord Genuity Initiates Coverage On Akero Therapeutics with Buy Rating, Announces $36 Price Target

Canaccord Genuity analyst Edward Nash initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Buy rating and a $36 price target.

Benzinga · 02/10/2020 11:28

Canaccord Genuity analyst Edward Nash initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Buy rating and a $36 price target.